首页> 外文期刊>Naunyn-Schmiedeberg's Archives of Pharmacology >Differential inhibition of (3H)-oxotremorine-M and (3H)-quinuclinidyl benzilate binding to muscarinic receptors in rat brain membranes with acetylcholinesterase inhibitors.
【24h】

Differential inhibition of (3H)-oxotremorine-M and (3H)-quinuclinidyl benzilate binding to muscarinic receptors in rat brain membranes with acetylcholinesterase inhibitors.

机译:(3H)-oxotremorine-M和(3H)-苯并喹啉亚基苯甲酸酯与乙酰胆碱酯酶抑制剂对大鼠脑膜中毒蕈碱受体结合的差异抑制。

获取原文
获取原文并翻译 | 示例
           

摘要

The potential interaction of acetylcholinesterase inhibitors with cholinergic receptors may play a significant role in the therapeutic and/or side-effects associated with this class of compound. In the present study, the capacity of acetylcholinesterase inhibitors to interact with muscarinic receptors was assessed by their ability to displace both [3H]-oxotremorine-M and [3H]-quinuclinidyl benzilate binding in rat brain membranes. The [3H]-quinuclinidyl benzilate/[3H]-oxotremorine-M affinity ratios permitted predictions to be made of either the antagonist or agonist properties of the different compounds. A series of compounds, representative of the principal classes of acetylcholinesterase inhibitors, displaced [3H]-oxotremorine-M binding with high-to-moderate potency (ambenonium>neostigmine=pyridostigmine=tacrine>physostigmine> edrophonium=galanthamine>desoxypeganine) whereas only ambenonium and tacrine displaced [3H]-quinuclinidyl benzilate binding. Inhibitors such as desoxypeganine, parathion and gramine demonstrated negligible inhibition of the binding of both radioligands. Scatchard plots constructed from the inhibition of [3H]-oxotremorine-M binding in the absence and presence of different inhibitors showed an unaltered Bmax and a reduced affinity constant, indicative of potential competitive or allosteric mechanisms. The capacity of acetylcholinesterase inhibitors, with the exception of tacrine and ambenonium, to displace bound [3H]-oxotremorine-M in preference to [3H]quinuclinidyl benzilate predicts that the former compounds could act as potential agonists at muscarinic receptors. Moreover, the rank order for potency in inhibiting acetylcholinesterase (ambenonium>neostigmine=physostigmine =tacrine>pyridostigmine=edrophonium=galanthamine >desoxypeganine>parathion>gramine) indicated that the most effective inhibitors of acetylcholinesterase also displaced [3H]-oxotremorine-M to the greatest extent. The capacity of these inhibitors to displace [3H]-oxotremorine-M binding preclude their utilisation for the prevention of acetylcholine catabolism in rat brain membranes, the latter being required to estimate the binding of acetylcholine to [3H]-oxotremorine-M-labelled muscarinic receptors. However, fasciculin-2, a potent peptide inhibitor of acetylcholinesterase (IC50 24 nM), did prevent catabolism of acetylcholine in rat brain membranes with an atypical inhibition isotherm of [3H]-oxotremorine-M binding, thus permitting an estimation of the "global affinity" of acetylcholine (Ki 85 nM) for [3H]-oxotremorine-M-labelled muscarinic receptors in rat brain.
机译:乙酰胆碱酯酶抑制剂与胆碱能受体的潜在相互作用可能在与此类化合物相关的治疗和/或副作用中起重要作用。在本研究中,乙酰胆碱酯酶抑制剂与毒蕈碱受体相互作用的能力是通过其在大鼠脑膜中取代[3H]-氧代苯甲酸-M和[3H]-喹啉亚基苯甲酸酯结合的能力来评估的。 [3H]-苄基喹啉亚基/ [3H]-氧代苯甲酸-M的亲和力比允许预测不同化合物的拮抗剂或激动剂性质。代表乙酰胆碱酯酶抑制剂主要类别的一系列化合物以高至中等的效力置换了[3H]-氧代remorine-M结合(氨苯ne>新豆tig碱=吡啶并os胺=他克林> phy豆碱> edrophonium =加兰他敏>脱氧花氨酸),而只有a烯和他克林取代[3H]-喹啉亚基苯甲酸酯的结合。抑制剂如脱氧peganine,对硫磷和草胺对两种放射性配体的结合抑制作用可忽略不计。在不存在和存在不同抑制剂的情况下,通过抑制[3H]-氧代苯甲酸-M结合而构建的斯卡查德图显示出不变的Bmax和降低的亲和常数,表明潜在的竞争或变构机制。除他克林和ase烯之外,乙酰胆碱酯酶抑制剂取代结合的[3H]-氧代remorine-M优先于[3H]喹啉亚基苯甲酸酯的能力预示了前一种化合物可能在毒蕈碱受体上充当潜在的激动剂。此外,抑制乙酰胆碱酯酶的效力的等级顺序(氨苯甲醚>新斯的明=草毒碱=他克林>吡啶并嘧啶= edrophonium =加兰他敏>脱氧peganine>对硫磷>甘氨酸)表明,最有效的乙酰胆碱酯酶抑制剂也取代了[3H]-氧代remorine-M最大程度。这些抑制剂具有取代[3H]-氧代短素-M结合的能力,因此无法用于预防大鼠脑膜的乙酰胆碱分解代谢,后者需要评估乙酰胆碱与[3H]-氧代短素-M标记的毒蕈碱的结合。受体。但是,fasciculin-2是一种有效的乙酰胆碱酯酶肽抑制剂(IC50 24 nM),确实可以通过[3H] -oxotremorine-M结合的非典型抑制等温线阻止大鼠脑膜中的乙酰胆碱分解代谢,因此可以估算“乙酰胆碱(Ki 85 nM)对大鼠脑中[3H]-氧代短素-M标记的毒蕈碱受体的“亲和力”。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号